Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mirna Therapeutics

Request full access

Biotechnology research and development company focused on miRNA-directed oncology therapies

Austin, United StatesFounded 2007Biotech & Life Sciences

About Mirna Therapeutics

Mirna Therapeutics, Inc. was a clinical-stage biopharmaceutical company that operated in the oncology therapeutics market, focusing on a field known as microRNA (miRNA) replacement therapy. The company was founded by Matthew M. Winkler in 2007 and was incorporated in Delaware as a wholly-owned subsidiary of Asuragen, Inc., before being spun out to Asuragen's stockholders in December 2009. The foundational research and drug discovery program that led to Mirna's creation began as early as 2002 at Ambion, Inc. and was later continued at Asuragen. This extensive scientific groundwork, led by the company's scientists, established that certain naturally occurring miRNAs function as tumor suppressors and that their levels are often diminished in cancerous tissues.

The company's core business strategy was centered on developing miRNA mimics to restore the function of these lost tumor suppressor miRNAs in cancer cells. This approach, termed miRNA replacement therapy, aimed to re-regulate multiple oncogenic pathways simultaneously, a departure from many cancer therapies that target single genes or pathways. Mirna's business model involved advancing its proprietary pipeline of miRNA drug candidates through clinical trials, with the goal of commercializing these novel oncology therapeutics. The company also sought partnerships with other pharmaceutical and biotechnology firms to leverage its intellectual property. Its operations were financed through a combination of private funding rounds, federal and state grants, and eventually, public equity. Dr. Paul Lammers, who was not a founder but joined as President and CEO in 2009, was instrumental in steering the company through its major financing and clinical phases. His background includes extensive executive, clinical, and regulatory experience at companies like EMD Serono and Organon, which was vital for navigating the complex drug development process.

Mirna's lead product candidate was MRX34, a mimic of the naturally occurring miR-34, encapsulated in a liposomal nanoparticle formulation for delivery. It was the first miRNA mimic to enter human clinical trials for cancer and was being evaluated for treating various solid tumors, including liver cancer, and hematological malignancies. A significant milestone was achieved in October 2015 when Mirna Therapeutics went public, listing on the NASDAQ under the ticker "MIRN" and raising approximately $43.8 million in its initial public offering. However, the company's trajectory dramatically changed in September 2016 when it voluntarily halted the Phase 1 clinical trial of MRX34. This decision was prompted by the observation of multiple severe immune-related adverse events in patients. Following this setback, the company suspended further research and development activities and began exploring strategic alternatives to enhance stockholder value. This process culminated in a reverse merger with Synlogic, Inc., which was announced in May 2017 and completed in August 2017. The merger effectively ended Mirna's independent operations, with the combined entity continuing under the Synlogic name and focusing on Synlogic's synthetic biology platform.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2015
Open positions
None listed
Dealroom signal
59.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Testing, Biotechnology, Oncology, Genetics and genomics, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit Oct 2015 $0 — Undisclosed —
POST IPO EQUITY✓Other financing Oct 2015 $17M — Pfizer Ventures —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Mirna Therapeutics website traffic

Latest recorded traffic for Mirna Therapeutics is 160 monthly website visits, down 55.6% over the last three months.

Latest monthly visits160 3-month web change-55.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mirna Therapeutics in the Austin ecosystem

Live from Dealroom

The Mirna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later12 investors entered at this stage

  • Sofinnova Investments
  • Correlation Ventures
  • Osage University Partners
  • NEA
  • PTV Healthcare Capital
  • Morningside
  • Eastern Capital
  • Sante Ventures
  • Rock Springs Capital
  • Celgene
  • Baxter Ventures
  • Pfizer Ventures
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Austin HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mirna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mirna Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.